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I. INTRODUCTION: A NATION CONFUSED
"Where you stand depends on where you sit" is the motto Dr. Sally Satel
applied to the differing reactions of British and American drug regulation
agencies to prescribing antidepressants to children and adolescents.' In the
past few years, the idea that antidepressants could trigger suicidal behavior in
adolescents and children "has migrated from the margins of the medical
community to the front pages of the newspapers" in countries around the
world.2
Sixteen years have passed since the first approval of Prozac, and yet many
questions remain unanswered concerning the drug and other antidepressants
like it, particularly concerning their effects on both adults and children.' There
is heavy debate in countries around the world over the safety of using
antidepressants in children and adolescents.' Critics claim that the drugs
increase suicidal behavior while drug companies and other supporters deny
such claims.'
The question is one of a balancing of evils. All drugs carry the risk of some
side effects; therefore those confronted with a condition that may be eased or
cured by a certain medication must weigh the chance of a cure against the
possibility of serious side effects.6 The balancing act is particularly critical
when confronting antidepressant use in children. Patients who are prescribed
antidepressants are "by definition, vulnerable to suicidal behavior."7
Therefore, it is often "difficult to determine where the effects of depression
end and the effects of the drug begin."' Untreated depression can itself be
l Sally Satel, M.D., Antidepressants: Two Countries, Two Views, N.Y. TIMES, May 25,
2004, at F6, available at 2004 WLNR 5408038.
2 Jonathan Mahler, The Antidepressant Dilemma, N.Y. TIMES, Nov. 21, 2004, § 6, at 59,
available at 2004 WLNR 12058669.
3 Stacy Burling, Depression Drug Data Leave Many Questions, PHILA. INQUIRER, Oct. 4,
2004, at EO1, available at 2004 WLNR 3694217.
4 See, e.g., Satel, supra note I (referring to debates in Great Britain and the United States);
see also No Antidepressant Is Without Side Effects, HINDUSTAN TIMES, May 8, 2005, available
at 2005 WLNR 7226627 (showing the debate in the Asian News); Agnes Bongers Drugs Gone
Bad, HAMILTON SPECTATOR, Sept. 22, 2004, at G05, available at 2004 WLNR 6118568
(referring to the database in Canada).
See, e.g., Mahler, supra note 2.
6 See Committee on Safety of Medicines (CSM) Working Group, Questions and Answers
on Findings of CSM Expert Working Group, http://www.mhra.gov.uk/news/2004/SSRIsQA
061204.pdf (last visited Sept. 10, 2005).
' Mahler, supra note 2.
8 Id.
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fatal; as such, one must be sensitive to the possibility that an outright ban on
antidepressant use in children poses a significant danger.9 On the other hand,
the presence of these drugs on the market could be endangering millions of
U.S. adolescents who are unknowingly taking medications that may increase
suicidal thoughts and behaviors.'0
Some critics argue that if antidepressants increase the chance of suicidal
behavior, they should not be used. However, an American Psychiatric
Association representative warned that the Food and Drug Administration
(FDA) should not frighten away those patients who need treatment."l
Fassler and others in his camp recognize that, in treating people already
prone to suicidal tendencies, the antidepressants may be unfairly blamed for
increasing those tendencies. 2 Ultimately, parents coping with a depressed or
aggressive child must weigh the possible risks of the treatment against the
possible rewards. 3 The decision is a tough one, one that no parent wants to
make, and one that is further complicated because doctors and parents across
the United States are currently without adequate information.
This Note will explore the law and the differing reactions of the regulatory
agencies of the United States and Great Britain to the negative and sometimes
devastating effects of antidepressant use in children, adolescents, and teens.
This Note will show that Great Britain's outright ban on antidepressant use
(with the exception of Prozac) in children is arguably less favorable than the
United States' delayed warnings. The Note will also trace the problems of the
corruption and dissemination of misleading data as precursors to the present
state of confusion and fear surrounding this topic. Finally, this Note will argue
that, in order for parents and doctors to make informed decisions about
antidepressant use in children, there must be legislation enacted to restrict the
control that drug companies currently exercise over the information provided
to the public and to the medical community at large.
9 Editorial, Information Needed; Drug Companies Should Be Required to Publish
Unfavorable Studies, COLuMBUS DISPATCH, Nov. 7, 2004, at 4C, available at 2004 WL
97824351 [hereinafter Information Needed].
10 Id.
" Shankar Vedantam, FDA Confirms Antidepressants Raise Children s Suicide Risk, WASH.
POST, Sept. 14, 2004, at A01 (Fassler predicted that "[h]alf of all kids who suffer from
depression will attempt suicide at least once, and at least 7 percent will die as a result").
12 See id.
13 See Bonnie Miller Rubin, Parents Face Dilemma When Kids Need Meds; Saying No to
Using Psychiatric Medications, With Their Side Effects, Brings the Possibility of Other Risks,
CHI. TRI., Nov. 7, 2004, at C 11, available at 2004 WL 99090852.
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H. BACKGROUND
In the past two generations, Western society's conception of childhood has
changed and, consequently, so has the conception of childhood mental health
problems. 4 Before the late 1980s, "childhood depression was viewed as very
rare" and "different from adult depression," and so not treatable with
antidepressants. 5 However, times have changed. 6
Childhood depression has become a popular notion, reflecting the
broader cultural changes that have taken place in our view of
childhood and its problems. These days we are as likely to use
medicalised terminology to describe children's feelings (such as
depressed) as we are less pathological descriptions (such as
unhappy). 7
During this time, youth suicides have also increased. 8 Research for an
amendment to the Public Health Service Act found that over four thousand
children and young adults commit suicide each year, and that the suicide rate
amongst children and young adults tripled from 1952 to 1995.'9
In the past decade, there has been a correlate increase in the diagnosis of
childhood depression.2 0 This may be attributed to "a lowering of the threshold
for [a] diagnosis" as a result of"a change in the meaning we give to childhood
unhappiness."'E However, there is evidence that kids today are less happy than
the children of past generations.2
" Sami Timimi, Rethinking Childhood Depression, http://www.critpsynet.freeuk.com/Re
thinkingdepression.htm (last visited Sept. 10, 2005).
15 Id.
16 See id.
17 Id.
8 Garrett Lee Smith Memorial Act Amendments of 2004, Pub. L. No. 108-355, § 2, 118
Stat. 1404 (2004).
19 Id.
20 Timimi, supra note 14 (noting "[a]t the end of 2003, over 50,000 children were prescribed
antidepressants, and over 170,000 prescriptions a year for antidepressants were issued to people
under 18 years old in the United Kingdom").
21 Id.
22 Id. (noting "there may also be a genuine increase in the amount of unhappiness
experienced by children as a result of growing up in a cultural context that has seen huge
changes in child rearing practices, family structures, lifestyles, and education").
[Vol. 34:159
2005] "WHERE YOU STAND DEPENDS ON WHERE YOU SIT" 163
These unhappy kids are increasingly being treated with antidepressants."
A study conducted in 2002 found that the number of Americans undergoing
psychotherapy rose slightly from 1987 to 1997, yet there was a substantial drop
in the time patients waited in consulting rooms.24 Most interestingly, "the
percentage of patients who combined psychotherapy with psychiatric
medication nearly doubled."25 All in all, psychotherapy patients are spending
less time on the couch and more time in the pharmacy.
There is tension over the use of antidepressant drugs in children and
adolescents, not only between differing countries like Great Britain and the
United States, but also among the doctors and psychologists within those
countries. At the epicenter of this medical and moral debate is selective
serotonin reuptake inhibitors (SSRls) and the question of their effect on an
entire generation of young patients.
A. The Difficulty of Treatment Involving SSRIs
The popularity of the SSRIs may be due, in part, to their low side effects
when compared to other classes of antidepressants.26 There are nine
antidepressants known as SSRls, or "serotonin blocker" drugs, including drugs
such as Prozac (fluoxetine), Zoloft (sertraline), and Paxil (paroxetine). 27 SSRIs
fight depression by blocking the central nervous system's uptake of serotonin,
a chemical that "allows individual neurons to communicate with one another.
Serotonin has been shown to play a role in multiple psychiatric disorders,
including depression."28 The FDA has approved only one of these drugs,
Prozac, to treat depression in children and adolescents.29 However, "doctors
are free to prescribe any of these drugs 'off label' for a patient group not
23 Erica Goode, Psychotherapy Shows a Rise over Decade, but Time Falls, N.Y. TINEs, Nov.
20, 2002, at A21, available at 2002 WLNR 3547468.
24 Id.
25 Id.
26 See May L. Harris, Problems with Prozac: A Defective Product Responsible for Criminal
Behavior?, 10 J. CONTEMP. LEGAL ISSUES 359, 362 (1999).
27 See FDA Requires 'Black Box' Warning on Use of SSRIs in Children: Panel Limited by
Lack of Reliable Data, 14 MENTAL HEALTH WKLY., Sept. 27, 2004, available at 2004 WLNR
3141625 [hereinafter FDA Requires 'Black Box' Warning]; see also John Alan Cohan,
Psychiatric Ethics and Emerging Issues ofPsychopharmacology in the Treatment ofDepression,
20 J. CONTEMP. HEALTH L. & POL'Y 115, 117-18 (2003).
28 Catherine M. Vale, The Rise and Fall of Prozac: Products Liability Cases and "The
Prozac Defense" in Criminal Litigation, 12 ST. Louis U. PuB. L. REv. 525, 527-28 (1993).
29 FDA Requires 'Black Box' Warning, supra note 27.
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specified on the packaging., 3' Therefore, many types of SSRls are prescribed
to children, adolescents, and adults, "not only for psychotic illnesses but other
conditions such as manic depression, Alzheimer's, personality disorders, and
nonpsychotic depression."'"
A major concern about the use of SSRIs in children is the difficulty of
accurately diagnosing mental illness.32 "[P]inpointing a mental illness is
harder than diagnosing a physical one."33 In children, the symptoms of mental
illness can be "vague-such as stomachaches and irritability. 3 4 Also, many
symptoms of disorders overlap.35 Given these difficulties, and taking into
account "the normal ups and downs of adolescence.... diagnosis becomes
even more art than science."36 The diagnosis and treatment of children with
mental illness is further obfuscated because "many on the front lines of
children's health-pediatricians, family practice physicians-are not trained
to detect warning signs" of childhood depression.37 Furthermore, because
"depression is the main psychiatric condition leading to suicide, it seems
reasonable to infer that rises in antidepressant prescribing, which indicate
improved management of depression, should have a beneficial effect on
suicide rates. 38 Yet, finding direct evidence linking suicide prevention and
antidepressants is difficult.39
Because of the lack of dependable evidence, it is not yet clear why
antidepressants seem to increase suicidal tendencies in adolescents and not in
adults, nor exactly how the increase was first detected.40 Professor John Mann,
30 Mahler, supra note 2.
3' Cohan, supra note 27, at 118.
32 See Rubin, supra note 13.
33 Id.
34 Id.
35 Id.
36 Id.
31 Id. (quoting Paul Raebum).
3' David Gunnell & Deborah Ashby, Antidepressants and Suicide: What is the Balance of
Benefit andHarm?, 329 BMJ 33, 34 (2004), http://bmj.bmjjoumals.com/cgi/reprint/329/7456/
34.
" Id. at 34-36 (noting that this lack of direct correlating evidence is probably attributable to
two basic reasons: 1) even among people with serious depression, "suicide is rare" so "most
clinical trials have insufficient power to provide clear evidence on the effect of antidepressants
on suicide," and 2) because the concept "that treatments for depression might increase suicide
risk" is counterintuitive, "the possibility may not have been specifically investigated in the
clinical trials").
40 Id. at 36 (noting "[tihe increased risk in children may have been detected either because
of the increased prevalence of suicidal thoughts and self harm in young people.., or because
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believes "there is something different in depression in children and adolescents
versus adults."'"
In understanding depression in children, one must recognize that "the
symptom profile is strikingly different" '42 from that of adults. Depression in
adolescents and children can be particularly difficult to manage because
"[t]eenagers are often resistant to psychotherapy, and unlike adults, who can
quit a job or leave a marriage that might be aggravating their unhappiness,
adolescents are almost always stuck with their lots. ' 43 Teenage depression
"isn't the consistently down, sad, depressed feeling that adults have."' These
factors have laid the groundwork for the crisis now facing Great Britain and
the United States.
B. Great Britain 's Approach
On December 10, 2003, "Fears of Suicide Link Bring Child Drugs Ban"
was the headline of The Evening Standard, and paper after paper took up the
topic.45 On that day, the Medicines and Healthcare Products Regulatory
Agency (MHRA) banned doctors in Great Britain from prescribing any
antidepressant except Prozac because of new evidence showing that the drugs
could be linked to suicidal behavior.46
The MHRA was formed in April 2003 and is an executive agency of Great
Britain's Department of Health. 47 The MHRA's aims include "promoting the
safe use of medicines and devices" throughout Great Britain, making sure
the absence of beneficial effects meant that adverse effects dominated the clinical picture")
(footnote omitted).
4' Regulatory News FDA: To Study Antidepressants' Effect on Suicidal Thoughts in
Children, 10 Am. HEALTH NETWORK, Sept. 28, 2004 (noting that "[y]ounger people may have
less control over their impulses or less ability to cope with or understand an unexpected drug
effect") [hereinafter Regulatory News FDA].
42 Sharon Begley, Developing Problem: Why Depression Looks Different in a Kid's Brain,
WALL ST. J., Oct. 15, 2004, at Al (quoting Harold Koplewicz, a psychiatrist from New York
University Medical Center).
43 Mahler, supra note 2.
4 Begley, supra note 42 (quoting Carol Glod of McLean Hospital).
41 Paul Sims, Fears of Suicide Link Bring Child Drugs Ban, EVENING STANDARD (London),
Dec. 10, 2003, at 22, available at 2003 WL 69699027; see also Andrew Clennell, Threat of
Suicide Leads to Ban of MajorAntidepressantsfor Children, INDEPENDENT (London), Dec. 10,
2003, at 6, available at 2003 WLNR 9418933; Sarah Boseley, Drugs for Depressed Children
Banned, GUARDIAN (London), Dec. 10, 2003, at 1, available at 2003 WLNR 4671409.
46 Sims, supra note 45.
47 Id.
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medicines sold in Britain "are of an acceptable standard of safety, quality and
efficacy," and "ensuring that medical devices meet appropriate standards of
safety, quality and performance."'t 8
The British Medicines Act of 1968 gave the appropriate Ministers (the
current MHRA) power to make regulations imposing requirements on the
labeling of medicinal containers and packages. 9 One purpose of this power
is that appropriate information and warnings will be provided and that no false
or misleading evidence will be given.5"
Acting under this explicitly given power, the MHRA enacted a ban as a
result of an investigation into clinical trials conducted by drug companies.5
The investigation began as a study of the suicidal and withdrawal symptoms
suffered by adults taking SSRIs, but the investigation soon took a turn toward
the effects on children and adolescents. 2 Safety concerns arising from the
pharmaceutical companies' clinical trials prompted the MHRA to take action. 3
The findings included reports of "insomnia, agitation, weight loss, headache,
tremor, loss of appetite, self harm and suicidal thoughts.' Great Britain
found the risk that the SSRIs may increase suicidal thoughts or actions in
children and adolescents greater than the reward the drugs presented to those
same children. An MHRA press release announcing the ban stated that the
majority of SSRIs were not suitable to be used in children and adolescents
under eighteen, as studies found those risks to be greater than the benefits of
using SSRIs to treat those under eighteen.5 Metaphorically speaking, British
officials happened upon a playground where a landmine lay and decided that
ordering the children off the playground was in everyone's best interest.
48 About the MHRA, Medicines and Healthcare Products Regulatory Agency Website, http://
www.mhra.gov.uk/aboutmhra/aboutmhra.htm (last visited Sept. 10, 2005).
41 Medicines Act, 1968, c. 67, § 85 (Eng.).
5o Id. § 85(2)(b) (Another purpose stated under subsection (2)(c) is "promoting safety in
relation to medicinal products").
5' See Press Release, MHRA, Safety Review of Antidepressants Used By Children
Completed (Dec. 11, 2003), http://www.mhra.gov.uk/news/ssri-101203.htm (noting that "the
MHRA is the executive arm of the UK's Drug Licensing Authority and is responsible for all
aspects of the regulation of medicines in the UK").
52 Sims, supra note 45.
53 Id.
54 Questions and Answers: Advice on SSRIs in Children from the Committee on Safety of
Medicines, http://medicines.mhra.gov.uk/ourworklmonitorsafequalmed/safetymessages/ssriqa
_101203.pdf (last visited Sept. 10, 2005).
" Press Release, supra note 51.
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The December 2003 ban followed months of warnings, studies, and
weighing of the risks and rewards of these drugs.5 6 The British agency
recognized a problem and moved swiftly to alleviate it by banning all except
one of the SSRIs in children. However, Britain may have moved too swiftly
by not giving enough consideration to the possibility that these drugs may
successfully treat some depressed children. 7
The alacrity with which Great Britain banned these drugs may be attributed
to a medical culture very different from that of the United States. Dr. David
G. Fassler, a child psychiatrist at the University of Vermont College of
Medicine, said, "the British think we [the United States] overdiagnose and
overtreat children" and Professor Frank Furedi, a sociologist at the University
of Kent, agreed that Britain is "more cautious about medicalizing the problems
of children." 8
The differences in medical culture between the two countries can be traced
to their medical systems. Patients in Great Britain do not have the choice of
medication that is afforded to U.S. patients.5 9 Britain's National Health
Service chooses what medications its physicians will prescribe and, therefore,
"Americans have more autonomy in choosing doctors and negotiating
treatments. ,
60
As a result, when it came time to react, Great Britain, lacking a strong
cultural and financial investment in antidepressants in general, decided that
any risk of harm to their children was too high and urged doctors not to use
certain antidepressants. 6' The FDA instead chose to be more deliberate in
56 See Gordon Duff, Selective Serotonin Reuptake Inhibitors-Use in Children and
Adolescents with MajorDepressive Disorder (Dec. 10, 2003), http://medicines.mhra.gov.uk/our
work/monitorsafequalmed/safetymessages/cemssril 01 203.pdf (noting that the Expert Working
Group of the CSM had finished its study of the "safety and efficacy of the SSRI class in the
treatment of pediatric major depressive disorder," and had "advised that the balance of risks and
benefits for the treatment of major depressive disorder ... in under 18s is judged unfavourable
for sertraline, citalopram and escitalopram, and unassessable for fluvoxamine." Therefore, the
MHRA held these drugs to be contraindicated in treating major depressive disorder in children
under eighteen. The CSM found only fluoxetine (Prozac) "to have a favorable balance of risks
and benefits" in children.).
" See Gregory K. Fritz, FDA Decision on SSRls Oversimplifies Suicide Risk, 20 BROWN U.
CHILD & ADOLESCENT BEHAV. LETTER 8, Nov. 1, 2004, available at 2004 WL 70828697.
58 Satel, supra note 1.
59 Id.
60 Id.
61 Id.
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acquiring evidence, more cautious in its approach, and more gradual in taking
action.
C. The United States'Approach
In its mandate, the FDA, "empowered by various Congressional acts,...
can set standards for product quality and ingredients, require that new types of
products be proven safe before they are marketed, demand that labeling and
advertising be clear and truthful, and enforce the recall of hazardous
products."62 The FDA ensures that drugs sold in the United States are "safe
and effective."63 After initial approval of a drug, the FDA can withdraw
approval if new scientific data on clinical trials show the drug to be "unsafe"
or if there is a deficit in the amount of evidence showing that the drug will
have the results it claims.M The FDA also regulates warnings on drugs. The
law provides that labeling should "be revised to include a warning as soon as
there is reasonable evidence of an association of a serious hazard," and that
causality does not have to be shown.65 Furthermore, the federal regulation
mandates that certain warnings must be included, but does not prohibit the
inclusion of additional warnings.66 Therefore, FDA regulations as to warning
standards have been found by most courts to be only minimum standards,
which do not preempt failure to warn claims under state law.67 Manufacturers
are permitted to strengthen warning labels without prior FDA approval if they
feel such measures are necessary for the safety of their consumers. 68
Following the ban in Great Britain in December 2003, the FDA met on
February 2, 2004 to discuss possible courses of action. On that day, risk data
regarding antidepressant usage by children was presented by the
Psychopharmacologic Drugs Advisory Committee (PDAC) and the Pediatric
Advisory Committee (PAC).69 It was not until September 13,2004, when FDA
62 Christopher Placitella & Justin Klein, The Civil Justice System Bridges the Great Divide
in Consumer Protection, 43 DUQ. L. REv. 219, 220 (2005). See generally 21 U.S.C.A. § 352
(West 1999); 21 U.S.C.A. § 355 (West 1999); 21 U.S.C.A. § 360 (West 1999).
63 21 U.S.C.A. § 393(b)(2)(B) (West 1999). See also 21 U.S.C.A. § 355(d) (West 1999).
21 U.S.C. § 355(e) (2003).
65 21 C.F.R. § 201.57(e) (2005).
66 See Hill v. Searle Labs., 884 F.2d 1064, 1068 (8th Cir. 1989); Motus v. Pfizer, Inc., 127
F. Supp. 2d 1085, 1092 (C.D. Cal. 2000).
67 Hill, 884 F.2d at 1068; Motus, 127 F. Supp. 2d at 1092.
68 See 21 C.F.R. § 314.70 (2005).
69 Jeanne Lenzer, FDA Hearings Confirm Risks of Antidepressants, 329 BMJ 641 (2004),
available at http://bmj.bmjjoumals.com (search "Author" for Lenzer," "Vol" for "329" and
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officials reported that an analysis of fifteen clinical trials (some of which were
not made public for years) found a" 'consistent link' between the use of...
antidepressant[s] and suicidal tendencies in children. 7
The PDAC and PAC met again on September 14, 2004, voting fifteen to
eight in favor of a "black box" warning in regard to antidepressant use in
children.7 A black box warning "consist[s] of a black section with white
writing that appears at the top of inserts distributed to physicians and patients"
and is the strongest warning issued by the U.S. government, short of an
outright ban.72
One of the missions of the FDA is to "promote the public health by
promptly and efficiently reviewing clinical research and taking appropriate
action on the marketing of regulated products in a timely manner."73
Therefore, the question of whether the FDA "did their job" in the matter of
antidepressant use in children is really whether "appropriate action" was taken,
given the circumstances.
Kenneth Duckworth, a board certified psychiatrist, issued a statement in
response to the new black box warning labels; he admits that the FDA
recognized the need for providing doctors and parents with complete
information, close monitoring to manage the risk, and a clear warning of the
danger of antidepressant drug use in treating depression in children.74
However, Duckworth vehemently objected to the black box warnings.75 To
Duckworth, and to many other critics, the "incomplete" black box warning
creates the risk that doctors may simply be discouraged from prescribing
antidepressants in cases where children and adolescents are in danger of
suicide even without the drugs.76 "The resulting dilemma is familiar to parents
of children with any severe psychiatric disorder: put kids on drugs and risk the
side effects, or forgo medication and risk the potentially severe consequences
"Page" for "641").
70 Regulatory News FDA, supra note 41.
71 FDA Requires 'Black Box' Warning, supra note 27.
72 Inside the Industry Antidepressants: 'Black Box' Warnings to Appear in Mid-March, 10
AM. HEALTH NETWORK, Mar. 2, 2005.
73 21 U.S.C.A. § 393 (West 1999).
71 Child Psychiatrist Comments on FDA Warning Labels for Pediatric Antidepressants,
MED. LETTER ON THE CDC & FDA, Nov. 21, 2004, available at 2004 WLNR 7585962.
" Id. (stating that the warnings do not clearly state the risk of suicide nor "recognize that
antidepressants combined with psychotherapy represents the most effective course of
treatment").
76 Id.
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of untreated mental illness."" Britain, rather than have its citizens make this
judgment call, banned the use of SSRIs in children, except Prozac. 8
Although Britain may have, arguably, acted prematurely, the FDA required
drug companies to put forward details of any studies done on antidepressants
in children and adolescents in early 2004 and did not render a decision until
months later.79 The eight month delay in issuing a decision occurred because
the collected data needed to be reclassified.8" The findings suggested that two
or three of every one hundred patients "would be at risk for increased
suicidality, twice the rate of those on placebo."'"
Despite the reclassification, questions about the accuracy of the clinical
trials remain. Matthew Rudorfer, a physician with the National Institute of
Mental Health, Division of Services and Intervention Research, complained
"[t]here was no systematic way of collecting this information" and that most
of the trials the group reviewed were "scientifically flawed. 82
The FDA asked for guidance from the PAC and PDAC on questions such
as "whether the increased risk of suicidality applied to all nine drugs, all
antidepressants, only certain classes of antidepressants, or only certain
antidepressants." 3  The committees, after much deliberation, voted
unanimously for the black box warning.84
The decision came, however, amid allegations of scandal surrounding the
FDA's treatment of the issue. "Internal memos and a secret government report
about the negative effects of antidepressants in children" were published on
July 26, 2004 by the Alliance for Human Research Protection, a national
network whose purpose is promoting ethical standards in medical research.85
As a result of the media attention, Andrew D. Mosholder, an epidemiologist
in the FDA's Office of Drug Safety, was finally able to present his data at the
September 2004 meeting where he asserted that twenty-four studies
"confirmed his finding of 'an association of suicidality with antidepressant
7 Rubin, supra note 13.
78 Satel, supra note 1.
79 FDA Requires 'Black Box' Warning, supra note 27.
80 See id.
81 Id.
82 Id. (Rudorfer believed the studies were scientifically flawed because" '[t]hey were not
designed to capture a signal for suicidality' ").
83 Id.
8 See id.
85 Jeanne Lenzer, Secret US Report Surfaces on Antidepressants in Children, 329 BMJ 307
(2004), available at http://bmj.bmjjounals.com (search "Author" for "Lenzer," "Vol" for "329"
and "Page" for "307").
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treatment.' "86 Mosholder had not been allowed to present his findings at the
February 2, 2004 meeting because FDA officials had "considered the findings
to be inconclusive and thought the data would be 'alarming.' ",87 Drug
companies had been able to influence the studies by emphasizing the facts they
wanted, while deemphasizing negative results that may have been found.88
While senior FDA officials declined to share this information with the
public in early 2004, they now acknowledge that Dr. Mosholder's earlier
conclusion was justified. 9 Nevertheless, Robert J. Temple, the FDA's
associate director for medical policy, defended the decision to delay the
issuance of an official public warning.9 ° Critics argue, though, that the FDA's
tardiness in reacting to the British ban on the drugs not only injected panic,
that could have been avoided, into the situation, but also allowed unsuspecting
children to take medicine without possessing the appropriate information to
weigh the risks versus the rewards of the medication.9
Many educated in the field of child and adolescent psychology, however,
find the tardy black box warning to be an extreme step that is unwarranted in
the face of the available evidence. Gregory K. Fritz, a child and adolescent
psychiatrist, recognized that the "black box warning" "is the highest level of
alert" the FDA could give, absent taking the drug off the market.92 Therefore,
such a warning "has the potential to eliminate or drastically curtail the use of
antidepressants in patients under 19 years of age." 93 Fritz argued that "given
the available data, the benefits of carefully prescribed and monitored
antidepressant treatment far exceed the risk that taking one of these
medications will precipitate suicide."94
86 FDA Requires 'Black Box' Warning, supra note 27 (noting that these studies reported on
short-term data only, "so long-term risks are still unknown").
87 Id.
88 See id. ("The blame is clear. The money, power and influence of the drug industry
controls all.").
89 Vedantam, supra note 11; Lenzer, supra note 69.
90 Vedantam, supra note 11 (Temple said, "[w]e are cognizant that taking these drugs might
increase suicidal ideation. But depression alone is a cause of potential suicide, so scaring people
needlessly and overdoing it is worrisome also.").
91 See Antidepressant Makers Withhold Data on Children (Jan. 19, 2004), http://www.
healthyplace.com/Communities/Depression/news/antidepressants-data-withheld.asp [hereinafter
Antidepressant Makers Withhold Data].
92 Fritz, supra note 57.
93 Id.
94 Id.
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Indeed, the warnings have had a noticeable effect. Since the issuance of the
black box warnings, the number of children in the United States taking
antidepressants has substantially decreased according to data released by,
pharmacy benefit manager, Medco Health Solutions.95 Therefore, although the
United States has not banned SSRIs. The insinuation of danger maybe acting
as a de facto prescription.
III. THE PROBLEM: CONTROVERSY AND MISLEADING DATA
Doctors and parents cannot accurately evaluate the risks and rewards of
antidepressants for children while drug companies control the dissemination
of information regarding clinical trials.
Megan Kellar, seventeen, took Paxil every day since elementary school. 96
When the FDA issued its warning, she continued with her twenty milligrams
every morning, as she had for seven years. 97 "I felt like I was in a box. It was
dark, and I couldn't get out," Megan said of her life before Paxil.98 Her mother
feels that "[Paxil] saved her life." Success stories like Megan's suggest that
the British ban on antidepressants is ill-advised because it has denied access
to drugs that could save the lives of depressed children.
Unfortunately, many stories have unhappy endings. At the hearings held
to aid the FDA in their regulatory recommendation process stories were told
by "[p]arents of children who had hung, shot, or stabbed themselves to
death."99 These parents claimed that a side effect of the SSRIs "drove their
children to suicide."' 00 U.S. parents now blame the FDA for its tardiness in
warning the nation of these known dangers, and are looking for recourse in the
courts from the drug companies for children's lives needlessly and painfully
lost. 0 '
9' Michael Johnsen, FDA Mulls Stronger Warning for Antidepressants, 26 DRUG STORY
NEWS 8 (Oct. 11, 2004), available at 2004 WL 94003410 (noting that "[t]he Medco report
show[ed] an 18 percent decrease in the number of patients younger than 18 on an antidepressant
in the first quarter of 2004 and an additional 5 percent decrease in the second quarter, which
contrasts sharply to the steady quarterly growth in the number of antidepressants dispensed for
pediatrics since 2002").
96 Anti-depressants for Kids: Lifesaver or Suicide Risk? (Mar. 11, 2004), http://www.
healthyplace.com/Communities/Depression/news/children-antidepressants_4.asp.
97 Id.
98 id.
9' Lenzer, supra note 69.
100 Id.
"01 See, e.g., Miller v. Pfizer, Inc., 356 F.3d 1326 (10th Cir. 2004).
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A. Corruption in the System
The scandal involving "internal memos and a secret government report
about the negative [side] effects of antidepressants in children" published
belatedly in the summer of 2004 left many in the United States confused and
angry with the FDA." 2
The FDA's clinical investigation system is carried out by FDA approved
investigators and sponsors."°3 As such, the FDA is not carrying out these
clinical drug trials."°  However, if the FDA determines that a clinical
investigation should not go forward because the subjects would be exposed to
an unreasonable or significant risk of injury or other problems, it can, and
must, place the investigation on "clinical hold."' 5 Sponsors, who, in our
scenario, would be the pharmaceutical companies, are the ones responsible for
carrying out these investigations. Their duties include, but are not limited to
"selecting qualified investigators, providing them with the information they
need to conduct an investigation properly, ensuring proper monitoring of the
investigation(s) ... and ensuring that FDA and all participating investigators
are promptly informed of significant new adverse effects or risks with respect
to the drug."' °6 This last responsibility is what many critics believe the drug
company sponsors have failed to do over the years."0 7
As a strategic tactic, on Friday, November 5, 2004, the FDA reported its
hiring of the Institute of Medicine, a private nonprofit group, to analyze the
FDA's drug approval process and also "named an independent appeals panel
for its own staff' to protect against impropriety."0 ' Since the scandal, the
102 Lenzer, supra note 85.
103 See 21 C.F.R. § 312.3 (2005)
Investigator means an individual who actually conducts a clinical
investigation (i.e., under whose immediate direction the drug is administered
or dispensed to a subject) .... Sponsor means a person who takes
responsibility for and initiates a clinical investigation. The sponsor may be
an individual or pharmaceutical company.... The sponsor does not actually
conduct the investigation unless the sponsor is a sponsor-investigator.
See also 21 C.F.R. § 312.50 (2005) (describing the responsibilities of a sponsor); 21 C.F.R. §
312.53 (2005) (describing how to select a qualified investigator).
104 See 21 C.F.R. § 312.3 (2005).
105 See 21 C.F.R. § 312.42 (2005) ("A clinical hold is an order issued by FDA to the sponsor
to delay a proposed clinical investigation or to suspend an ongoing investigation.").
106 21 C.F.R. § 312.50 (2005).
107 Information Needed, supra note 9.
108 Editorial, Too Much Secrecy Our Position: The FDA Needs to Let Consumers Know when
there is a Problem with a Drug, ORLANDO SENTINEL, Nov. 9, 2004, at A12.
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FDA's credibility has been questioned, and these moves were necessary to
bolster what credibility the FDA had left with the U.S. public.'19
Dr. Steven Galson, acting director of the FDA's Center for Drug Evaluation
and Research, admitted the FDA does not "always understand the full
magnitude of drug risks prior to approval."'"10 He insists, however, that the
issue of antidepressant use in children was an "exception in a process that
usually work[s] smoothly."' Nevertheless, Dr. Galson "announced five steps
that he said would guarantee the FDA ha[s] 'the best post-marketing drug
safety program in the world.' "' 2
But critics say, even with this five-step program, the FDA is too easily
bought. "This is a cosmetic move by the FDA," said Dr. Sidney Wolfe of the
Public Citizen's Health Research Group in response to the new program.'3
Critics posit "the measures did not go far enough to correct . .. the
pharmaceutical industry's excessive influence on the agency."
'
"
4
B. A Need for Accurate Data
Inadequate studies and data are a leading cause of most of the confusion
surrounding the antidepressant situation, both in Great Britain and the United
States. This deficiency results from the control pharmaceutical companies
exert over the information disseminated from the clinical studies. Dr.
Lawrence Diller warned, "[t]here is a growing credibility gap between
frontline doctors and the leadership in the profession. The blame is clear. The
money, power and influence of the drug industry controls all.""''
109 See id.
10 Ricardo Alonso-Zaldivar, FDA Creates Safety Plan; Following Two Incidents of Risky
Side Effects, the Agency Announces New Measures to Monitor Drugs. But Critics Say That is
Not Good Enough, L.A. TIMES, Nov. 6, 2004, at A 1l.
111 Id.
12 Id. (These steps "include filling the post of FDA drug safety director, which has been
vacant for about a year," "creating a process that would allow dissenting opinions about the
safety of a drug to reach agency superiors," "ask[ing] the Institute of Medicine, one of the
National Academies, to study the U.S. drug safety system," "conduct[ing] workshops with
experts on drug safety risks and... issu[ing] guidelines to the industry for monitoring adverse
reactions to medications.").
113 Id.
"4 Id. (Dr. Wolfe was quoted as saying, "There is a serious problem in the failure of the FDA
to be more cautious in approving drugs their own physicians say are too dangerous").
15 FDA Requires 'Black Box' Warning, supra note 27.
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Studies deeming a drug to be "effective are three times more likely to be
published than those showing a drug doesn't work or does more harm than
good."" 6 Ironically, the very pharmaceutical companies that bear an interest
in a drug's approval, fund the studies on the safety, effectiveness, and side
effects of that drug." 7 These companies are able to influence the studies by
emphasizing the data favorable to them while deemphasizing any negative
results." 8 The freedom pharmaceutical companies are given in conducting
clinical trials not only skews results, but also leaves doctors wanting for the
facts they need to make accurate prescription decisions. "9
Oddly, many of the clinical studies on the use of SSRIs in children were
conducted after the drugs were approved by the FDA. 2 ° There are benefits
that encourage post-approval testing: drug companies often conduct these types
of tests to secure patent extensions on their drugs. 2 ' However, most
companies are granted extensions regardless of whether the drugs were
effective.' 22 Of course, a published study of negative findings is not good for
sales. Therefore, drug companies have an incentive to alter or hide any
negative findings. Evidence has shown that drug companies have manipulated
their research findings so that the studies published do not match up with the
real results.'23
The possibility of drug companies withholding negative findings is not a
problem in the United States alone. The MHRA became aware of a safety
issue with one SSRI from trials that had been completed in 1996, but whose
results were not made public until 2001.124 One critic of antidepressant drug
use in children has said "[c]onflicts of interest and the company control of the
data have thrown out the scientific method .... If hundreds of trials don't
work out, they don't publish them, they don't talk about them."'25 Darrel
Regier, director of the division of research, American Psychiatric Association
has called for "a journal of negative findings."'126
116 Karen Barth Menzies, A Cure Worse than the Disease, 41 TRIAL 20, 22 (2005).
117 See Burling, supra note 3.
118 See id.
119 See id.
120 Id.
121 Id.
122 Id.
123 Menzies, supra note 116.
124 Sims, supra note 45.
125 Antidepressant Makers Withhold Data, supra note 91 (quoting Vera Hassner Sharav,
patients rights advocate).
126 Id.
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In both the United States and Great Britain, big companies with big money
have been able to keep big secrets quiet. Yet keeping this negative data a
secret over the years has caused physicians, psychiatrists, and the public to
receive conflicting information, resulting in contradictory advice being given
to patients and their families. Great Britain dealt with this fear through a
possibly premature ban of the use of SSRIs in children. In both countries,
however, the secrets have brought forth heightened fear and uncertainty." 7
C. The First Step Js a Big One
The first step to solving the problem of how to balance the risks versus the
rewards of SSRI use in children is adequate and forthright data.'28
Specifically, the question is whether SSRIs are to blame for an increased
suicide rate in children who take the drugs.'29 Great Britain quickly reacted to
the danger they recognized in antidepressant use in children, arguably without
all the data needed to support such a decision. 30 Accurate data is imperative
if doctors, patients and their families are to make an informed risk versus
reward analysis in each case."'3 The accuracy of trial reports is vital to good
medical care.'32 Both the United States and Britain are in need of these reports
to accurately assess the dangers of antidepressant drug use in children and
adolescents. '33
Plaintiffs' lawyers are already bringing forth claims that manipulation of
drug studies constituted fraudulent promotion and, therefore, should be
actionable.'34 If these claims are allowed to go forward in mass quantities, it
will immediately and significantly curb the pharmaceutical companies'
influence on the clinical trials.'35 Chief Justice John Marshall wrote that "[t]he
very essence of civil liberty certainly consists in the right of every individual
'27 See id. For more solutions see Trudo Lemmens, Leopards in the Temple: Restoring
Scientific Integrity to the Commercialized Research Scene, 32 J.L. MED. & ETHICS 641 (2004).
128 See Jon N. Jureidini et al., Efficacy and Safety of Antidepressants for Children and
Adolescents, 328 BMJ 879 (2004), available at http://bmj.bmjjournals.com (search "Author" for
"Jureidini," "Vol" for "328" and "Page" for "879").
129 See id.
130 See supra Part Il.B.
131 See Jureidini et al., supra note 128.
132 Id.
133 See id.
134 See generally Menzies, supra note 116.
135 See id. at 28.
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to claim the protection of the laws, whenever he receives an injury."' 36
Suddenly, amidst risks of fines and punishment, consumer complaints are not
readily disregarded by drug manufacturers.'37
Still, impartial and comprehensive clinical trials are probably a better path.
Yet, money is an issue. Whether the government or the drug companies step
forward, the consumers will most likely bear the ultimate costs in the form of
higher taxes or higher drug prices. 3 '
Currently, drug companies foot the bill for the studies and are responsible
for acquiring the data.'39 Although it is legal for drug companies to withhold
or camouflage these negative findings by mixing them with positive findings,
at the very least, such questionable tactics highlight a moral failure on the part
of the industry. 40 The truth, imperative to accurate treatment, should not be
suppressed. 4'
To correct the withholding of data, legislation mandating the full disclosure
of evidence by the drug companies should be enacted. The issue then becomes
how to shape the law to bring about such disclosure.
Mr. Kenneth I. Kaitin, director of Tufts Center for the Study of Drug
Development, insists he has "never seen a situation where a drug company
encouraged the manufacturing of a drug that was potentially unsafe."' 42 Still,
drug companies are known for putting drugs on a fast approval track by
pushing for faster FDA approval thereby "increas[ing] the risk that a
medicine's side effects are not fully known" because of the lack of time for
adequate research. 4
3
Yet, drug companies are rightly concerned that study information will be
used unfairly against them. Cathryn Clary, Pfizer executive, while recognizing
136 Marbury v. Madison, 5 U.S. 137, 163 (1803).
137 Klein, supra note 62, at 230-31 (recognizing "[t]he civil justice system makes
manufacturers responsible to the individual, and therefore is a powerful recourse for a citizen
harmed by a defective or dangerous product").
138 See Lauren Hammer Breslow, The Best Pharmaceuticals for Children Act of 2002: The
Rise of the Voluntary Incentive Structure and Congressional Refusal to Require Pediatric
Testing, 40 HARv. J. ON LEGIS. 133, 133 (2003).
13' Burling, supra note 3.
140 See Antidepressant Makers Without Data, supra note 91.
141 Id. (stating that Welsh psychiatrist, David Healy, "rejected the notion that the safety
information could be treated like any other private property" and said that data should be in "the
public domain in their entirety").
142 AlexBerenson, TrialLawyers Are Now Focusing on Lawsuits Against Drug Makers, N.Y.
TIMES, May 18, 2003, § 1, at 1, available at 2003 WLNR 5211730.
143 Id.
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the need for full and accurate data, insisted that "small sample sizes in trials
'run the risk of magnifying or diminishing a signal. Releasing an individual
study can be as misleading as it is helpful.' "'" Moreover, "[a]ll drugs have
side effects, and even the safest approved drugs have side effects."' 145
D. Are the Drugs Really to Blame?
From a public health perspective, drug companies should not be liable for
every injury that is a result of their drug. Every drug is not going to work in
every patient, no matter how safe it is. 14' The "greater good" is a compelling
argument regardless of the percentage of the population who may not respond
favorably to a particular drug, but it is a hard argument to make when a family
is rightly concerned with the health of their child as opposed to that of an
unknown quantity of unrelated patients. 47 Yet, Dr. John Walkup, a child
psychiatrist, insisted that it is "dangerous to make public policy based on rare
and tragic events."'"1 In calculating the risks versus rewards, it should be
recognized that "[f]or patients with conditions that have a high risk of suicide,
such as severe depression, the risk-benefit balance may be more favourable
than for patients with conditions such as anxiety and mild depression, in which
suicide is rare."'4 9
There is little adequate research available to show the long term effects of
psychiatric drug use in children. 5 ° Confidence in the accuracy of data that is
published is imperative. 5' Publishing independent studies that accurately
reflect both the benefits and risks of each drug would allay much of the fear
and debate surrounding the issue.' 52
'" Antidepressants Makers Withhold Data, supra note 91.
145 Berenson, supra note 142 (quoting Dr. Janet Woodcock who went on to say that "[i]t is
very likely that the newer classes of drugs in general are safer than older drugs, but you have to
recognize that many more people are taking medicines now than used to").
Id. (quoting Dr. Kin-Wei Chan, "[n]o medicine is completely safe for everyone").
147 Id. ("For a family it's not one in a thousand or one in a million, it's one in one" admitted
Dr. Kin-Wei Chan, who otherwise argued that drug companies cannot fairly be expected to know
every short or long term effect of their drugs).
148 Mahler, supra note 2.
149 Gunnell & Ashby, supra note 38 ("It is in these lower risk conditions, however, that much
of the recent rise in prescribing has probably occurred.") (footnote omitted).
IS0 See id.
151 See Jureidini et al., supra note 128.
152 See id.
[Vol. 34:159
"WHERE YOU STAND DEPENDS ON WHERE YOU SIT"
An informed patient may lead to better therapy and, therefore, to a more
successful recovery. 153 Realistically, however, many patients are unable or
unwilling to become "completely informed." '154 Patients instead rely on what
they read in the newspapers or watch on the television.55 As a result, patients
may get the "stigmatized Cliff Notes version of antidepressant therapy." '156
Consequently parents in the United States may, out of fear, refuse any kind of
pharmacotherapy treatment, including SSRIs, for their children.'57 Depressed
children, possibly predisposed to suicidal thoughts or behaviors, may be left
with only "talk" therapy for treatment, or with no treatment at all.
158
The question remains: are the drugs really to blame or are the suicides
attributable to the depression itself? Antidepressant "drugs give patients more
energy before affecting their depression, enabling a person to act on a suicidal
impulse."'59 This phenomenon is known as "rollback."' 6 ° Psychiatrists have
been aware of rollback "for decades"; and it is not limited to SSRIs.161 The
question then becomes: whether patients taking SSRIs who committed suicide
were experiencing rollback, or whether there was "something specific about
[SSRIs] that triggered suicidal impulses" in those patients.'62 While some
doctors argue that antidepressants increase suicidal tendencies in some
patients, there is an overall lack of reliable evidence.'63
All of the clinical studies submitted to the FDA, save one, were submitted
under the Pediatric Exclusivity Act."6 The Pediatric Exclusivity Act'6 5 is a
1997 law "meant to encourage more research studies by offering an additional
six months of marketing exclusivity (pediatric exclusivity) if, in accordance
153 Johnsen, supra note 95.
154 Id.
155 Id.
156 Id.
157 Id.
158 Id.
' Regulatory News FDA, supra note 41.
160 Mahler, supra note 2.
161 Id.
162 Id.
163 See id. See also Gunnell & Ashby, supra note 38 ("[C]urrent concerns about the safety
of SSRIs come from clinical trials both of too short duration (10 weeks) to identify longer term
beneficial effects and are carried out in children and adolescents, among whom suicide is rare.").
16 FDA Requires 'Black Box' Warning, supra note 27.
165 21 U.S.C.S. § 355a (2005).
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with the requirements of the statute, the sponsor submitted requested
information relating to the use of the drug in the pediatric population."' 66
Today, many doctors, patients, and their families are calling for higher
quality research into antidepressant use in children. The FDA committees and
members of the public, along with the American Medical Association and the
American Academy of Child and Adolescent Psychiatry, have "endorsed the
development of a national clinical trials registry, where all clinical trials would
be available for public access on the Internet."'67 Also, the Pharmaceutical
Research and Manufacturers of America (PhRMA) has put in place new
guidelines which require the results of clinical trials regardless of whether the
results are favorable toward the company.'68
It is possible to imagine, however, that pharmaceutical companies will have
even more incentive to tamper with the data in order to protect their interests.
Therefore, the legal system needs to step in with civil and criminal sanctions
in this area to protect against drug companies dealing in their own self-
interests. These unaltered studies are an absolute necessity if the United States
and the world at large is to make an informed and accurate choice on the use
of antidepressants in children.
IV. WHERE THE LAW SHOULD TAKE US FROM HERE
The balance of risks and benefits of SSRIs are unclear and may, admittedly,
"vary depending on an individual's underlying suicide risk."'69 If one relies
on the premise that even good drugs are going to have side effects, why the
recent increase in mass litigation? 7° There is, of course, only one answer:
lawyers.' 7
With modem technology, attorneys can lure plaintiffs from all over the
United States. "Plaintiffs' lawyers can now finance enormously complicated
166 Id.
167 id.
168 Id.
169 Gunnell & Ashby, supra note 38 ("Any antidepressant induced suicides may be offset by
the beneficial effects of antidepressants on depression and long term suicide risk associated with
untreated depression.").
170 See, e.g., Miller, 356 F.3d at 1336; see also Cartwright v. Pfizer, Inc., 369 F. Supp. 2d 876
(E.D. Tex. 2005); Blanchard v. Eli Lilly & Co., 207 F. Supp. 2d 308 (D. Vt. 20002); Motus, 127
F. Supp. 2d 1085.
171 See Berenson, supra note 142 ("[P]laintiffs' lawyers acknowledge that much of the
momentum behind the suits comes from the increasing aggressiveness and wealth of the trial
bar.").
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suits that require years of pretrial work and substantial scientific expertise, in
the hope of a multibillion-dollar payoff." '172 A Google'73 search of the internet
will find a number of web pages with contact information for plaintiffs'
attorneys across the country that do this type of work. One such site has an
SSRI online questionnaire and provides links, such as "Do I Have a Case?,"
along with assurances that their "firm is ready to pursue your case anywhere
in the country."' 7 4 The expense and inefficiency of these law suits could be
avoided if legislation existed to regulate the dissemination of information from
clinical trials.
A. Doctors'Decisions Based on Exposure to Possible Lawsuits
General practitioners who prescribe antidepressants to children and
adolescents may be slapped with a medical malpractice suit due to the black
box warnings. 75 "These physicians are critical members of the treatment team
with many children and adolescents with serious psychiatric disorders."' 76
Unlike Great Britain's decisive move, the FDA's seeming indecision has left
the U.S. medical community in a quandary. Because U.S. parents and doctors
are scared, both are unable to help the depressed children: the ones who are
truly terrified.
Because of the chance of future suits, some companies have started
calculating the risk of law suits when making decisions about which new drugs
to consider.'77 This means avoiding legal problems is a dangerous proposition
in itself in this area of medicine. Drugs that are possibly dangerous, but that
may be used in successful treatment may never be produced because of the fear
of liability.'78 It seems inappropriate for the legal system to affect the ultimate
decisions of medical treatment.
172 Id. ("Scores of firms collaborate on a case, with some responsible for finding claimants,
others for managing the millions of documents that companies turn over, others for the written
legal arguments, and still others for presenting the case to a jury.").
173 Google is one of many internet search engines where one may access information by
"typing and clicking" search terms, instantly bringing up a world of knowledge on the topic.
' Cory, Watson, Crowder, and DeGaris, P.C., http://www.cwcd.com/CM/MassTorts/Mass
Torts51.asp (last visited Sept. 10, 2005).
175 Johnsen, supra note 95.
176 Id. (quoting Dr. David Fassler of the American Psychiatric Association).
1 Berenson, supra note 142 (quoting Kenneth I. Kaitin).
178 Id. (noting that companies "have mostly stopped developing contraceptives, which are
very vulnerable to lawsuits").
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B. Sadly "Real": Life Examples in the Law
Although it appears the antidepressant crisis came about suddenly, there
have been concerns and lawsuits over these issues for years. A Wyoming jury
set a legal precedent in finding a pharmaceutical company liable for a death
caused by a patient taking their antidepressant in 2001.179 The court held Paxil
caused Donald Schell to shoot and kill his wife, daughter, and granddaughter,
as well as commit suicide.18 Schell did have a past history of depression and
psychiatric treatment, but the court still deemed the drug company SmithKline,
complicit in his demise.'
Despite several suits involving antidepressant use in adults over the past ten
to fifteen years, there had been relatively few suits involving children and
adolescents before Miller v. Pfizer, Inc. 182 Matt Miller hanged himself from
a low-hanging hook in his closet less than a week after beginning his
prescription of Zoloft. All the while, his parents slept soundly in a nearby
room. Had Matt lowered his feet to the floor, he would have saved himself.'83
The judge, ultimately, barred the testimony of the plaintiffs expert and the
case was dismissed because the plaintiffs failed to show a causal link, that
SSRIs cause some people to become violent or suicidal.' The Court of
Appeals for the Tenth Circuit affirmed.'85 Despite the new black box
warnings, the U.S. Supreme Court declined to review the case.8 6
The invasion of privacy engendered by a lawsuit, combined with an
expensive process and an unsure outcome, is a serious deterrent to families
wanting to bring a suit against drug makers.'87 These problems will only be
solved by decisive federal legislation mandating impartial research and
regulating the dissemination of information from those impartial clinical
studies.
179 Tobin v. SmithKline Beecham Pharm., 164 F. Supp. 2d 1278, 1287-90 (D. Wyo. 2001).
"0o Id. at 1287.
18 Id. at 1288 (focusing on allegations that SmithKline failed to adequately warn the public
about potential side effects of Paxil).
'82 Miller, 356 F.3d 1326. See also Mahler, supra note 2.
13 Mahler, supra note 2.
' Miller, 356 F.3d at 1330.
185 Id. at 1336.
186 Miller v. Pfizer, Inc., 356 F.3d 1326 (10th Cir. 2004), cert. denied, 73 U.S.L.W. 3214
(U.S. Oct. 4, 2004) (No. 03-1505).
187 Mahler, supra note 2.
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C. Four Steps to Satisfying the Need
Recent media attention aimed at the use of SSRIs in children may,
ultimately, lead to positive changes in the treatment of these patients in the
United States, such as:
1) the funding of more, independent research on antidepressants
(and other psychoactive drugs used in children); 2)
comprehensive reporting of research results and open access to
all data; 3) a reduction in casual prescribing of SSRIs and more
careful monitoring of treatment; and 4) an increase in the number
of child and adolescent psychiatrists so that lack of access does
not result in inferior care for complicated patients.'88
Perhaps the only way to ensure that clinical studies on the effects of SSRI use
in children and adolescents are executed and reported correctly, and without
abuse, is for them to be regulated and funded by the government. Society has
looked to drug companies for answers, but the companies are not answering
public health questions.' 9 If we as a society want clear results unskewed by
the self-interest of the drug companies, then it seems we can either 1) create
those civil and criminal sanctions to protect against such tampering of results
by drug companies or 2) get an uninterested and unbiased group to perform the
tests and fund the tests with tax dollars.
Appropriate legislation is necessary to mandate that clinical trials of SSRIs
and all antidepressants must be of sufficient duration to detect not only short
term but also long term benefits. Improved testing is necessary if drug
companies, psychiatrists and parents are to be able to balance the benefits
against the possible risks associated with these drugs. 9 ° Trials must "also
systematically collect data on suicidal thoughts and behaviour."' 9'
However, in this very controversial sphere, it should be noted that the
clinical trials, themselves, are deemed by some to be unethical.' 92 Because
188 Fritz, supra note 57.
"89 Antidepressant Makers Withhold Data, supra note 91 (quoting Thomas R. Insel, director
of the National Institute of Mental Health).
190 Gunnell & Ashby, supra note 38.
191 Id.
192 Breslow, supra note 138, at 140. Breslow also notes that two recent U.S. statutes relating
to pediatric medicine do not mandate clinical testing of children, but rather, offer incentives to
encourage such testing. Id. at 134.
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children are particularly vulnerable, critics have argued that it is unethical to
subject them to clinical trials, that the trials hurt children more than help
them. 193
People on both continents and both sides of the issue recognize that there
must be an informed weighing of the risks against the rewards when
determining whether children should be treated with SSRIs. Great Britain
immediately reacted to the dangers of antidepressant use in children with an
absolute ban. Yet, Andy Vickery, a Houston attorney who has represented
many plaintiffs in SSRI cases, like many others, admitted, "I have never
disputed the fact that, when prescribed and monitored by the right doctor to
treat the right condition in the right patient, these drugs can help and have
helped a lot of people."' 94 Britain's harsh reaction to this volatile problem may
have seemed best at the time, but more information is needed to adequately
assess the risks and rewards of the use of these possibly life-saving or life-
ending drugs in children and adolescents. In both the United States and Great
Britain, further research and legislation is imperative so that doctors and
parents have the full and accurate data to make informed decisions about
antidepressant use in children. Legislation must restrict the control drug
companies currently exercise over the data provided to the medical community
and public.
V. CONCLUSION: A NATIONAL CALL FOR RELIABLE EVIDENCE
The safety of SSRI use in children and adolescents will continue to be
heavily debated regardless of the decisions made by the FDA, MHRA, or their
counterparts in other countries. Critics will continue to claim that SSRIs
increase suicidal behavior and are responsible for premature deaths. Drug
companies and other supporters of the medications will continue to deny these
claims and conduct clinical trials to support their stance, whether "fixed" or
accurate. This issue will remain highly controversial until satisfactory and
untainted research is conducted. Currently, clinical studies supporting both
sides of the issue have been published, but there does not seem to be a
preponderance of evidence supporting either side.
193 Id. at 136-40.
'94 Sara Hoffman Jurand, New Data Show Paxil May Increase Suicide Risk in Children, 39
TRIAL 75, 77 (2003) (Vickery went on to say, "[hjowever, I believe that physicians need to be
warned about the fact that their patients may well be in the small, vulnerable subpopulation of
people whose lives might be endangered by violent reactions to SSRIs").
[Vol. 34:159
"WHERE YOU STAND DEPENDS ON WHERE YOU SIT"
Therefore, each family, with the help of their child's doctor, must do a risk
versus rewards balancing test to determine if SSRI antidepressants are right for
their own child. Parents, doctors, and all involved should have an opportunity
to evaluate the risks versus the rewards critically, and then with much thought,
make a well-informed decision.
This issue can only be resolved if adequate information is supplied to
trained professionals and parents to allow them to make a well-informed
decision based on reliable data. That information will only be provided if it
is mandated by federal legislation requiring impartial clinical trials and
dissemination of information. If that goal is reached through criminal and civil
sanctions for self-dealing and inaccurate reporting so be it. Another option is
for the government to fund these studies and then demand reimbursement from
the drug companies. This would effectively incorporate the cost in the drug
price and pass that increase on to the consumers. A third option would be for
the government to hire a separate and impartial group to perform the clinical
trials, and pay them with tax revenue. In each case, the public will, most
likely, absorb the cost in some fashion, a disconcerting scenario amid the
current state of expensive medication.
Also, the studies must expand in duration to determine the long term effects
of these drugs on our nation's children. Whatever the path chosen for the
studies, full and mandatory disclosure, and the accurate reporting of that
disclosure through all media outlets is essential. Otherwise, the panic and fear
that has been fed by headlines and editorials across the country and fanned by
horror stories of children's hangings and shootings will continue to hurt all
parties involved.
Great Britain's MHRA probably acted prematurely when it so quickly
banned SSRI use in children. However, Britain did leave the possibility that
British children and adolescents whose doctors and parents deem such a course
appropriate, could be prescribed Prozac along with talk therapy. The FDA did
not take such extreme measures, but now the drug companies and the FDA
must face up to lawsuits and the fact that they may be responsible for some
children's and adolescents' deaths. There must be legislation that mandates
clinical trials that are executed immediately, accurately, and with full
disclosure to supply reliable data in this area, not only to assist in jury trials,
but most importantly to protect troubled children from themselves.
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